We came across a bullish thesis on Achieve Life Sciences, Inc. (ACHV) on Substack by Jacob Rowe. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc. (ACHV)'s share was trading at $3 as of Jan 23rd.
[caption id="attachment_517107" align="aligncenter" width="750"]Achieve Life Sciences (ACHV) presents a compelling investment opportunity, with its nicotine cessation drug, Cytisinicline, positioned to disrupt the market. The company has reached a significant milestone in its development, completing...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.